FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date Read more about FDA Classifies Prolia(TM) (Denosumab) Complete Response Submission and Targets Action Date
Amgen and Centocor Ortho Biotech Products Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA Read more about Amgen and Centocor Ortho Biotech Products Finalize ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA
Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share Increased 8 Percent to $4.91 Read more about Amgen's Fourth Quarter 2009 Adjusted Earnings Per Share Decreased 1 Percent to $1.05; Full Year 2009 Adjusted Earnings Per Share Increased 8 Percent to $4.91
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases Read more about Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium Read more about Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers Symposium
Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results Read more about Amgen Announces Webcast of 2009 Fourth Quarter and Full Year Financial Results
Amgen Donates $2 Million, Establishes Earthquake Relief Program Read more about Amgen Donates $2 Million, Establishes Earthquake Relief Program
Amgen to Present at the 28th Annual JP Morgan Healthcare Conference Read more about Amgen to Present at the 28th Annual JP Morgan Healthcare Conference
Amgen Resolves EPO Patent Dispute With Roche Read more about Amgen Resolves EPO Patent Dispute With Roche
Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines Read more about Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
